Related Experiment Video
Updated: Jul 9, 2026

14:59
Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
Published on: October 14, 2022
Two thousand Blalock-Taussig shunts: a six-decade experience
Jason A Williams1, Anshuman K Bansal, Bradford J Kim
1Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
The Annals of Thoracic Surgery
|November 27, 2007
Summary
The Blalock-Taussig shunt (BTS) is increasingly used for single-ventricle heart defects, with reduced use in tetralogy of Fallot. Operative survival has improved, reflecting its evolving role in congenital heart disease palliation.
Area of Science:
- Cardiology
- Pediatric Cardiology
- Congenital Heart Disease Surgery
Background:
- The Blalock-Taussig shunt (BTS) is a critical palliative procedure for congenital heart disease.
- Its application and outcomes have evolved over time, necessitating a review of long-term institutional experience.
Purpose of the Study:
- To analyze changes in the utilization and outcomes of the Blalock-Taussig shunt (BTS) over a 62-year period.
- To examine trends in patient demographics, diagnoses, and surgical approaches related to BTS.
Main Methods:
- A retrospective review of 2,016 Blalock-Taussig shunts performed between November 1944 and May 2006.
- Evaluation of hospital and autopsy records for patient data, operative details, complications, and long-term outcomes.
Main Results:
- Over 62 years, 2,016 BTS procedures were performed on 1,880 patients; 75% were classic BTS.
- Operative mortality decreased from 16% to 9% over the study period.
- There was a shift in diagnoses, with an increasing proportion of single-ventricle defects (5% to 34%) and decreasing use for tetralogy of Fallot.
Conclusions:
- The Blalock-Taussig shunt (BTS) shows decreased overall use, particularly for tetralogy of Fallot.
- Its application has increased for single-ventricle cardiac lesions.
- Improved operative survival rates demonstrate the evolving efficacy of BTS in managing complex congenital heart disease.
